BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
Subscribe To Our Newsletter & Stay Updated
